Nanobody-enabled monitoring of kappa opioid receptor states.
Che, T., English, J., Krumm, B.E., Kim, K., Pardon, E., Olsen, R.H.J., Wang, S., Zhang, S., Diberto, J.F., Sciaky, N., Carroll, F.I., Steyaert, J., Wacker, D., Roth, B.L.(2020) Nat Commun 11: 1145-1145
- PubMed: 32123179 
- DOI: https://doi.org/10.1038/s41467-020-14889-7
- Primary Citation of Related Structures:  
6VI4 - PubMed Abstract: 
Recent studies show that GPCRs rapidly interconvert between multiple states although our ability to interrogate, monitor and visualize them is limited by a relative lack of suitable tools. We previously reported two nanobodies (Nb39 and Nb6) that stabilize distinct ligand- and efficacy-delimited conformations of the kappa opioid receptor. Here, we demonstrate via X-ray crystallography a nanobody-targeted allosteric binding site by which Nb6 stabilizes a ligand-dependent inactive state. As Nb39 stabilizes an active-like state, we show how these two state-dependent nanobodies can provide real-time reporting of ligand stabilized states in cells in situ. Significantly, we demonstrate that chimeric GPCRs can be created with engineered nanobody binding sites to report ligand-stabilized states. Our results provide both insights regarding potential mechanisms for allosterically modulating KOR with nanobodies and a tool for reporting the real-time, in situ dynamic range of GPCR activity.
Organizational Affiliation: 
Department of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA. taoche@email.unc.edu.